Read our insights and commentary about pharmaceutical industry news and healthcare innovation globally. Subscribe to our monthly newsletter to keep up to date with our thought leadership, news, and updates.
Showing 5 of 124 posts
July 6, 2021 | Blogs
CBPartners Asia Pacific Center of Excellence team have analyzed the dynamics for drug products listed on China’s 2017 NRDL, and subsequent 2018 sales data, to better understand the commercial opportunity within China. Explore the research here.
June 17, 2021 | Infographics
What can be learned from the first use of Japan's new Cost-Effectiveness Assessment (CEA) system? Read CBPartners' infographic here.
June 2, 2021 | Blogs
The recently introduced Medical Fund Bill has potential to improve access to novel therapies applying for reimbursement in Poland, however, it is yet to be seen how the criteria for inclusion in the Fund’s list are clarified locally and whether a broader scope of therapies will be eligible for the scheme to deem the market more attractive for submissions.
May 25, 2021 | Blogs
Launching a novel combination therapy provides a unique set of challenges and opportunities when seeking to achieve positive pricing and access outcomes. In this article, CBPartners reviewed the pricing and access outcomes from prior novel immuno-oncology combinations and have developed considerations for manufacturers developing strategies for their future pipeline.
May 20, 2021 | Podcasts
In the first of a multi-part biosimilar podcast series, CBPartners Healthcare Consultants are joined by special guest Dr. Bhavesh Shah, Senior Director of Pharmacy Strategy at Boston Medical Center, to explore the evolving biosimilar landscape in the USA.